Overview

Etanercept (Enbrel) in Undifferentiated Spondyloarthritis

Status:
Unknown status
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The study has the aim to investigate the efficacy and safety of etanercept in patients with active undifferentiated spondyloarthritis (uSpA) over the period of 520 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Charite University, Berlin, Germany
Collaborator:
Rheumazentrum Ruhrgebiet
Treatments:
Etanercept